Cite
HARVARD Citation
Scagliotti, G. et al. (2016). A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy. Lung cancer. pp. 20-23. [Online].